Researchers from Charité - Universitätsmedizin Berlin argue that metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) should be viewed as interconnected and evolving disease trajectories rather than rigid diagnostic categories.
Key Findings
Current classifications rely on snapshot assessments of alcohol intake and metabolic status, but both exposures fluctuate over time. Prospective cohort data show substantial migration across subclasses within six months:
- 36% of initially MetALD individuals shifted to MASLD or ALD
- 32% of ALD patients transitioned toward MetALD or MASLD
- 11% of MASLD cases were reclassified
Alcohol exposure and metabolic dysfunction converge on shared pathogenic pathways, including lipotoxicity, oxidative stress, inflammation, and fibrosis.
Challenges in Alcohol Assessment
Self-reported alcohol consumption may underestimate true intake by up to 57.7%, creating uncertainty in subclassification.
The biomarker phosphatidylethanol (PEth) can reflect alcohol consumption over 1–3 weeks: levels below 20 ng/mL exclude clinically relevant intake, while above 200 ng/mL indicate harmful drinking.
Proposed Framework
The new approach calls for longitudinal reassessment integrating alcohol exposure, metabolic risk factors, fibrosis staging, and trajectory markers. Key recommendations include:
- Prioritize fibrosis risk stratification using non-invasive tests such as FIB-4 and vibration-controlled transient elastography (VCTE)
- Clinical trials may require repeated monitoring of alcohol exposure and metabolic status for accurate patient stratification